Skip to main content

Table 2 Incidence of nivolumab-induced pneumonitis and UIP diagnosis categories

From: Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis

  Total, n Any grade, n (%) ≥Grade 3, n (%)
Total 188 22 (11.7) 3 (1.6)
NSCLC 96 14 (14.6) 2 (2.1)
HNC / GC 92 8 (8.7) 1 (1.1)
No fibrosis, all tumor types 148 8 (5.4) 0
No fibrosis, NSCLC 70 4 (5.7) 0
No fibrosis, HNC/GC 78 4 (5.1) 0
Pre-existing ILD, all tumor types 40 14 (35.0) 3 (7.5)
Inconsistent with UIP, all tumor types 28 9 (32.1) 1 (3.6)
Possible UIP/UIP, all tumor types 12 5 (41.7) 2 (16.7)
Pre-existing ILD, NSCLC 26 10 (38.5) 2 (7.7)
Inconsistent with UIP, NSCLC 17 6 (35.3) 1 (5.9)
Possible UIP/UIP, NSCLC 9 4 (44.4) 1 (11.1)
Pre-existing ILD, HNC/GC 14 4 (28.6) 1 (7.1)
Inconsistent with UIP, HNC/GC 11 3 (27.3) 0
Possible UIP / UIP, HNC/GC 3 1 (33.3) 1 (33.3) a
  1. NSCLC non-small cell lung cancer, HNC head and neck cancer, GC gastric cancer, ILD interstitial lung disease, UIP usual interstitial pneumonia; a a case of HNC with possible UIP had grade 5 pneumonitis